Navigation Links
DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
Date:10/27/2010

CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under devel
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. DURECT Corporation Announces Third Quarter 2008 Financial Results
2. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
3. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
4. China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
5. Dynamic Ventures Corporations Information To Be Available Through Standard & Poors Market Access Program
6. Met-Pro Corporation Acquires Patented Biological Technology
7. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
8. Oxford Finance Corporation Sponsors 2010 Mid-Atlantic Bio
9. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
10. China Cord Blood Corporation to Launch Warrant Exchange Offer
11. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
(Date:7/28/2015)... , ... July 28, 2015 , ... VetStem Biopharma will ... stem cell credentialing course to local area veterinarians. , The tour and course will ... units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... RESEARCH TRIANGLE PARK, N.C., July 28, 2015  United ... its financial results for the second quarter ended ... nearly 300% as compared to the second quarter ... said Roger Jeffs, Ph.D., United Therapeutics, President and ... was due to an increase in the number ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , , , ... CADX ), a biopharmaceutical company focused on in-licensing, developing and ... announced today that the company will be presenting at the following ... Senior Vice President and Chief Commercial Officer Scott Byrd will ...
... , , FAIRFAX, Va., Sept. 9 ... provider of technology and strategic consulting services and solutions to government ... from the Cancer Prevention and Research Institute of Texas (CPRIT) to ... over five years, if all options are exercised. Work on the ...
... , , , ... donated one ton of vitamins to Conakry, Guinea, West Africa, ... the country, as well as rural villages in the area ... hundreds of people for a long period, with follow-up shipments ...
Cached Biology Technology:Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009 2SRA International Wins $16 Million Contract from Cancer Prevention and Research Institute of Texas 2SRA International Wins $16 Million Contract from Cancer Prevention and Research Institute of Texas 3
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... on the growing mobile commerce market announces a revised version of ... week. The commercial will air on CNBC in New ... Angeles and San Francisco metro ... commercial focuses on Wocket,s ability to replace all the cards in ...
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... (NK) immune system cells can be genetically modified to ... attack and kill leukemic cells. This finding, from researchers ... to improve the outcome of children who receive treatment ... , Results of the St. Jude study are published ...
... discovered that the shape of a protein on ... the human bloodstream. This,finding, published Dec. 16 online ... vaccine that is significantly more effective at,protecting children ... shape of a large, paddle-like molecule that,Streptococcus pneumoniae ...
... zero in on cancer cells spreading throughout the body, ... a whole new weapon in the fight against tough-to-treat ... University researchers. , The compounds, called synthetic migrastatin analogues, ... cells in mice, and are the first to target ...
Cached Biology News:Genetically modified natural killer immune cells attack, kill leukemia cells 2New comparative toxicogenomics database 2New comparative toxicogenomics database 3First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 2First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 3
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
... A-20 cells were cultured in RPMI 1640 with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
Biology Products: